Initial MBL cell counts and CLL clinical characteristics among the 12 individuals who progressed to CLL
| ID . | Major MBL type . | Minor MBL type . | ALC, 109/L . | Absolute B-cell count, cells per μL . | Major clonal absolute B-cell count, cells per μL . | Minor clonal absolute B-cell count, cells per μL . | Percent CLL-like MBL clonal count . | Percent atypical MBL clonal count . | No. of months from first MBL to date of CLL diagnosis . | Rai stage . | IGHV mutation status . | FISH status . | CLL treated . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | CLL-like | 45.8 | 70 | 0 | No | ||||||||
| 2 | CLL-like | 5.7 | 44 | Yes | |||||||||
| 3 | CLL-like | 44.5 | 56 | 0 | No | ||||||||
| 4 | CLL-like* | 2 | 253.6 | 137.1 | 54.6 | 28 | 0 | Yes | |||||
| 5 | CLL-like | 5 | 2267.1 | 2207.7 | 98.36 | 46 | 0 | No | |||||
| 6 | Atypical | CLL-like | 1.5 | 103.7 | 33.70 | 11.82 | 14.25 | 37.81 | 3 | Yes | |||
| 7 | CLL-like | 1.4 | 406 | 25.7 | 59 | I | Normal | No | |||||
| 8 | CLL-like | 2.7 | 579.8 | 44.2 | 104 | 0 | Normal | No | |||||
| 9 | CLL-like | 1.6 | 55 | 81 | II | 13q | Yes | ||||||
| 10 | CLL-like | 6.1 | 4099.8 | 4013.6 | 98.89 | 9 | 0 | ||||||
| 11 | Atypical | CLL-like | 8.8 | 13.15 | 84.8 | 19 | 0 | Unmutated | Tri 12 /13q | Yes | |||
| 12 | CLL-like | 2.3 | 54.5 | 60 | No |
| ID . | Major MBL type . | Minor MBL type . | ALC, 109/L . | Absolute B-cell count, cells per μL . | Major clonal absolute B-cell count, cells per μL . | Minor clonal absolute B-cell count, cells per μL . | Percent CLL-like MBL clonal count . | Percent atypical MBL clonal count . | No. of months from first MBL to date of CLL diagnosis . | Rai stage . | IGHV mutation status . | FISH status . | CLL treated . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | CLL-like | 45.8 | 70 | 0 | No | ||||||||
| 2 | CLL-like | 5.7 | 44 | Yes | |||||||||
| 3 | CLL-like | 44.5 | 56 | 0 | No | ||||||||
| 4 | CLL-like* | 2 | 253.6 | 137.1 | 54.6 | 28 | 0 | Yes | |||||
| 5 | CLL-like | 5 | 2267.1 | 2207.7 | 98.36 | 46 | 0 | No | |||||
| 6 | Atypical | CLL-like | 1.5 | 103.7 | 33.70 | 11.82 | 14.25 | 37.81 | 3 | Yes | |||
| 7 | CLL-like | 1.4 | 406 | 25.7 | 59 | I | Normal | No | |||||
| 8 | CLL-like | 2.7 | 579.8 | 44.2 | 104 | 0 | Normal | No | |||||
| 9 | CLL-like | 1.6 | 55 | 81 | II | 13q | Yes | ||||||
| 10 | CLL-like | 6.1 | 4099.8 | 4013.6 | 98.89 | 9 | 0 | ||||||
| 11 | Atypical | CLL-like | 8.8 | 13.15 | 84.8 | 19 | 0 | Unmutated | Tri 12 /13q | Yes | |||
| 12 | CLL-like | 2.3 | 54.5 | 60 | No |
ALC, absolute lymphocyte count; FISH, fluorescence in situ hybridization.
Baseline screening was no evidence of MBL.